Resmetirom improved HRQOL versus placebo in early MASH, particularly abdominal symptoms, disease-related worry, and health distress, with onset by week 24 and durability through week 52. Baseline ...

At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance on using resmetirom (Rezdiffra) and semaglutide (Ozempic, Wegovy) for metabolic ...

Please provide your email address to receive an email when new articles are posted on . In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering ...

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of ...

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety ...

CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis Noninvasive test data ...

Please provide your email address to receive an email when new articles are posted on . LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic ...

Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Resmetirom ...

WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...

Credit: Getty Images. Resmetirom is an oral thyroid hormone receptor-β selective agonist. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ...

CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension ...